|
|
|
| An Analysis of the Role of Fecal SFRP2 Gene Methylation Combined with Quantitative Immunochemical Fecal Occult Blood Test in Colorectal Cancer Screening |
| KANG Qian, XIE Hui, WANG Xin, et al |
| The Seventh Medical Center of PLA General Hospital, Beijing 100700, China |
|
|
|
|
Abstract Objective: To investigate the clinical significance of SFRP2 gene methylation combined with quantitative immunochemical fecal occult blood test for colorectal cancer screening. Methods: 106 patients with colorectal cancer,106 patients with advanced adenoma and 106 healthy people who underwent colonoscopy and pathology in the hospital's gastroenterology clinic were selected. Fecal samples were collected for Methylation-specific PCR to detect the methylation of fecal SFRP2 gene promoter and quantitative immunochemical fecal occult blood. Positive rate was calculated. Results: The positive rate of fecal SFRP2 gene methylation and positive QFIT were 77.35%,25.47%, 6.60%, 83.96%,15.09%, 1.87% in the colorectal cancer group, advanced adenoma group and control group, respectively. The cancer group and the advanced adenoma group were higher than the control group (P<0.05), and the colorectal cancer group was higher than the advanced adenoma group (P<0.05). The positive rate of SFRP2 methylation combined with QFIT was 91.51%, 52.83% and 5.66% in the colorectal cancer group, advanced adenoma group and control group, respectively. The detection rate of colorectal cancer group and the advanced adenoma group were higher than the individual test. (P<0.05). SFRP2 gene methylation in feces, the sensitivity of fecal occult blood quantification and combined detection were 77.35%, 83.96% and 93.40%,respectively, and the specificities were 93.40%, 98.11% and 93.40%, respectively. The sensitivity of the combined detection were higher than individual test (P<0.05). Conclusion: SFRP2 methylation combined with fecal occult blood quantification could improve the accuracy of screening colorectal cancer and have potential clinical value.
|
|
|
|
|
|
[1] 谭镜璁,仇玉兰.基于粪便样本的结直肠癌筛查技术概况[J].现代预防医学,2018,45(17):3178~3181.
[2] Schreuders EH, Ruco A,Rabeneck L,et al. Colorectal cancer screening: a global overview of existing programmes[J].Gut,2015,64(10): 1637~1649.
[3] 彭晨,蒋小华,姜景蔚,等.多靶点粪便基因检测在社区结直肠癌筛查中的应用价值研究[J].中国全科医学,2017,20(25):3132~3135.
[4] Siegel RL,Miller KD,Jemal A. Cancer statistics,2017[J]. CA- A Cancer Journal for Clinicians,2017,67(1) : 7~30.
[5] 刘洋.粪便SFRP2基因甲基化与结直肠癌的相关性研究[J].中国实验诊断学,2018,22(8):1354~1356.
[6] 文娟,李兆锦,蔡春.结直肠癌血液DNA甲基化的研究进展[J].广东医学,2016,37(7):1089~1091.
[7] 柏愚,刘晶,康倩,等.联合检测SDC2与SFRP2甲基化在结直肠癌筛查中的价值[J].中华消化内镜杂志,2019,36(6):427~432. |
|
|
|
2020, Vol. 26 
